News

EvolveImmune Therapeutics Reports Preclinical Data Highlighting Deep and Durable Anti-Tumor Efficacy with EV-104 in Presentation at 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) – SITC Poster available through this link

EvolveImmune Therapeutics Reports Preclinical Data Highlighting Deep and Durable Anti-Tumor Efficacy with EV-104 in Presentation at 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) – SITC Poster available through this link

Poster Spotlights CD2 Pathway as a Differentiated T Cell Costimulation Approach for the Treatment of Solid and Hematological Malignancies Modular Platform Being Leveraged to Advance Broad Pipeline of First-in-Category Costimulatory T Cell Engager Immunotherapies...

EvolveImmune Therapeutics Presents Promising Preclinical Data from Novel Costimulatory T Cell Engager Platform at American Association for Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy

EvolveImmune Therapeutics Presents Promising Preclinical Data from Novel Costimulatory T Cell Engager Platform at American Association for Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy

EVOLVE™ Platform Shows Promise as a Differentiated T Cell Costimulation Approach for the Treatment of Solid and Hematological Malignancies Presentation Highlights CD2 as an Optimal Costimulatory Target; Demonstrates Durable in vivo Anti-Tumor Efficacy with EVOLVE ...